Table 5 Univariate and multivariate cox proportional hazard analysis for H19 SNPs on HCC prognosis
VariablesAll HCC, n (%)Deaths, nMSTa (M)Univariate P-valueHazard ratio (95% CI)MultivariatecP-valueHazard ratio (95% CI)
n=286n=156
H19rs2735971GG193 (67.48)117 (75)47.0001 (Ref.)1 (Ref.)
AG85 (29.72)37 (23.72)52.0000.7691.06 (0.72–1.57)0.7520.94 (0.64–1.39)
AA8 (2.80)2 (1.28)33.0000.7561.12 (0.55–2.26)0.7630.80 (0.20–3.30)
n=344n=136
rs2839698CC182 (52.9)69 (50.7)56.0001 (Ref.)1 (Ref.)
CT144 (41.9)61 (44.9)48.0000.7760.95 (0.67–1.34)0.7161.07 (0.75–1.51)
TT18 (5.2)6 (4.4)78.4b0.5011.16 (0.76–1.76)0.4990.75 (0.32–1.73)
n=349n=137
rs3024270GG59 (16.9)21 (15.3)90.0001 (Ref.)1 (Ref.)
CG159 (45.6)67 (48.9)48.0000.7160.91 (0.56–1.49)0.8871.03 (0.71–1.49)
CC131 (37.5)49 (35.8)56.0000.8310.97 (0.75–1.26)0.8080.94 (0.56–1.58)
  • a, MST, median survival time (months).

  • b, Mean survival time was provided when MST could not be calculated.

  • c, Multivariate survival analysis was carried out by adding the age and gender variable to the clinicopathological parameters with P<0.05.